Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04420195 · ClinicalTrials.gov registry record · Phase 2
Envarsus XR in Lung Transplant
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04420195 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 41 participants.
The verdict
NCT04420195, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Patients undergoing a lung transplant will be enrolled. All patients will undergo lung transplantation with standard post-operative management, including triple immunosuppression. As soon as the patient is deemed appropriate to take medications via the oral route, they will be converted from IR tacrolimus to Envarsus XR. Patients will be followed per site's standard of care.
Interventions
- DRUG Extended-Release Tacrolimus
- DRUG Immediate-Release Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2022-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04420195
The ClinicalTrials.gov registry entry for NCT04420195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Extended-Release Tacrolimus is the first listed.
NCT04420195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04420195 about?
NCT04420195 is a clinical study titled "Envarsus XR in Lung Transplant". Patients undergoing a lung transplant will be enrolled. All patients will undergo lung transplantation with standard post-operative management, including triple immunosuppression. As soon as the patient is deemed appropriate to take medications via the oral route, they will be converted from IR tacr...
What is the current status of trial NCT04420195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2020-10-23. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT04420195?
The interventions under investigation include: Extended-Release Tacrolimus (DRUG), Immediate-Release Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT04420195?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.